Gene therapy - Where are we?

Lancet

Volumn 354, Issue SUPPL.1, 1999, Pages 1-4

  Smith, Alan E ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; VIRUS VECTOR;

CYSTIC FIBROSIS; ENZYME DEFICIENCY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0032789462     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Verma IM. Human gene therapy. Sci Am 1990; 263: 66-84.
2. Anderson WF. Human gene therapy. Nature 1998; 392 (suppl 6679): 25-30.
3. Boucher RC. Current status of CF gene therapy. Trends Genet 1996; 12: 81-84.
4. Rosenberg SA, Zhai YF, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90: 1894-900.
5. Rigg A, Sikora K. Genetic prodrug activation therapy. Mol Med Today 1997; 3: 359-66.
6. Lisziewicz J, Sun D, Smythe J, et al. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 1993; 90: 8000-04.
7. Smith AE. Viral vectors in gene therapy. Annu Rev Microbiol 1995; 49: 807-38.
8. Tseng WC, Huang L. Liposome-based gene therapy. Pharmaceut Sci Technol Today 1998; 1: 206-13.
9. Mullen CA, Snitzer K, Culver KW, Morgan RA, Anderson WF, Blaese RM. Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector. Hum Gene Ther 1996; 7: 1123-29.
10. Kaptein LC, Van Beusechem VW, Riviere I, Mulligan RC, Valerio D. Long-term in vivo expression of the MFG-ADA retroviral vector in rhesus monkeys transplanted with transduced bone marrow cells. Hum Gene Ther 1997; 8: 1605-10.
11. Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3: 1337-45.
12. Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol 1998; 72: 6014-23.
13. Lee ER, Marshall J, Siegel CS, et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther 1996; 7: 1701-17.
14. Armentano D, Zabner J, Sacks C, et al. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997; 71: 2408-16.
15. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3: 306-12.
16. Yei S, Mittereder N, Tang K, O'Sullivan C, Trapnell BC Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther 1994; 1: 192-200.
17. Molnar-Kimber KL, Sterman DH, Chang M, et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998; 9: 2121-33.
18. Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
19. Alton EWFW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999; 353: 947-54.
20. Tolstoshev P. Retroviral-mediated gene therapy - safety considerations and preclinical studies. Bone Marrow Transpl 1992; 9 (suppl 1): 148-50.
21. Ye X, Gao GP, Pabin C, Raper SE, Wilson JM. Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum Gen Ther 1998; 9: 2135-42.
22. Hehir KM, Armentano D, Cardoza LM, et al. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J Viral 1996; 70: 8459-67.
23. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75: 207-16.
24. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-83.
25. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17: 314-17.
26. Scaria A, St George JA, Gregory RJ, et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther 1997; 4: 611-17.
27. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis - initial clinical results with direct myocardial injection of phVEGF(165) as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-04.
28. Mack CA, Magovern CJ, Budenbender KT, et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 1998; 27: 699-709.
29. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-46.